We support people with disabilities. More than 2,800 clients of all ages count on us for living and working, day care and leisure, for 24/7 intensive care or limited, occasional support. Every day, 2,500 professionals and 1,000 volunteers are ready for them, in almost 100 locations or in their own or parental home in the Southeast Brabant region.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

news image

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More

Cell and Gene Therapy

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

news image

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More

Industrial Impact

UNITY BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH JOCASTA NEUROSCIENCE TO CONTINUE DEVELOPMENT OF Α-KLOTHO PROGRAM

UNITY | December 21, 2021

news image

UNITY Biotechnology, Inc. a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized to optimize synaptic neurotransmission of N-methyl-D-aspartate...

Read More

Medical

SLINGSHOT BIOSCIENCES, INC. PARTNERS WITH CAMBRIDGE BIOSCIENCE TO DISTRIBUTE SYNTHETIC CELLS THROUGHOUT UNITED KINGDOM AND IRELAND

Slingshot | June 16, 2022

news image

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot ...

Read More
news image

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More
news image

Cell and Gene Therapy

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More
news image

Industrial Impact

UNITY BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH JOCASTA NEUROSCIENCE TO CONTINUE DEVELOPMENT OF Α-KLOTHO PROGRAM

UNITY | December 21, 2021

UNITY Biotechnology, Inc. a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized to optimize synaptic neurotransmission of N-methyl-D-aspartate...

Read More
news image

Medical

SLINGSHOT BIOSCIENCES, INC. PARTNERS WITH CAMBRIDGE BIOSCIENCE TO DISTRIBUTE SYNTHETIC CELLS THROUGHOUT UNITED KINGDOM AND IRELAND

Slingshot | June 16, 2022

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot ...

Read More